GDM domain schema. The GDM schema summarizes the full set of data elements collected to represent the journey of a person living with cancer by integrating (i) foundational structured data encoded in routine clinical systems using standard terminologies (Fig. 2), (ii) high-value variables that often require manual abstraction from unstructured documentation, and (iii) derived variables calculated from (i) and (ii). The schema organizes elements into domains centered on the patient with cancer. The person-centered domain includes demographics, geographical linkage to area SDoH, individual-level SDoH (education, employment, marital status), hospitalization events, comorbidities, vital signs/performance status, and laboratory testing. The treatment-centered domain includes surgeries (procedures and pathology reports) and radiotherapy (course/phase, technique/modality, and dosimetry), systemic therapies (drug-level exposure with start/end dates and modification/discontinuation reasons), and clinical trial participation. The diagnosis-centered domain includes cancer diagnosis (ICD-O-3 tumor classification coding; diagnostic confirmation framework), cancer staging [grade, behavior, morphology, tumor–node–metastasis (TNM)], and genomic profiling of tumors (somatic alterations and sequencing panel metadata). Lastly, the outcomes-centered domain includes imaging (event dates, imaging types, radiologist assessment of cancer status and response) and clinical visits (event dates, visit types, and oncologist assessment of cancer status and response). The outcomes-centered domain also harmonizes temporally anchored tumor-centric assessments and person-centric measures to compute real-world endpoints, including overall survival (OS), progression-free survival (PFS), time to treatment discontinuation (TTD), time to next treatment (TTNT), and real-world response rate (rwRR). Together, these domains represent the complete GDM scope and illustrate how combining coded structured data with curated abstraction enables robust longitudinal phenotyping for real-world evidence generation. AE, adverse event; CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events; DOB, Date of Birth; ECOG, Eastern Cooperative Oncology Group; EOD, extent of disease; KPS, Karnofsky performance status; LTFU, Lost to Follow-Up; MGMT, O6-methylguanine-DNA methyltransferase; NDI, National Death Index; SDV, Source Data Verification; SSDI, Site-Specific Data Item. (Icon in this figure adapted from an image generated by ChatGPT, February 6, 2026, OpenAI, https://chat.openai.com.)